Tyr1035
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr1035  -  JAK1 (human)

Site Information
IEtDkEyytVkDDRD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448452
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 , 61 ) , mass spectrometry ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 39 , 41 , 42 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 51 , 52 , 54 , 55 , 58 ) , mutation of modification site ( 3 ) , phospho-antibody ( 3 , 4 , 14 , 20 , 30 , 47 , 53 , 56 , 57 , 59 , 61 , 62 ) , western blotting ( 3 , 4 , 14 , 20 , 30 , 47 , 53 , 57 , 59 , 61 , 62 )
Disease tissue studied:
adenoid cystic carcinoma ( 31 ) , bone cancer ( 5 ) , osteosarcoma ( 5 ) , breast cancer ( 4 , 30 ) , breast adenocarcinoma ( 4 ) , breast cancer, triple negative ( 4 ) , colorectal cancer ( 30 ) , colorectal carcinoma ( 30 ) , gastric cancer ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 21 , 39 , 49 , 52 ) , gastric carcinoma ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 21 , 39 ) , leukemia ( 50 , 54 ) , acute myelogenous leukemia ( 50 , 54 ) , liver cancer ( 53 ) , lung cancer ( 3 , 16 , 39 , 42 , 43 , 44 , 45 , 46 ) , non-small cell lung cancer ( 3 , 16 , 39 , 42 , 43 , 44 , 45 , 46 ) , non-small cell lung adenocarcinoma ( 16 ) , lymphoma ( 48 , 51 ) , Hodgkin's lymphoma ( 48 , 51 ) , ovarian cancer ( 19 , 41 ) , ovarian epithelial carcinoma ( 19 ) , multiple myeloma ( 14 ) , prostate cancer ( 30 ) , melanoma skin cancer ( 29 , 32 ) , rhabdomyosarcoma ( 5 ) , thymic carcinoma ( 17 )
Relevant cell line - cell type - tissue:
A204 (muscle cell) ( 5 ) , AU565 (breast cell) ( 4 ) , CHRF (megakaryocyte) ( 50 , 54 ) , COS (fibroblast) ( 61 ) , CTLL-2 (T lymphocyte) ( 61 ) , CV1 (fibroblast) ( 56 ) , DU 145 (prostate cell) ( 30 ) , FRTL-5 (thyroid cell) ( 62 ) , HCT116 (intestinal) ( 6 , 30 ) , HDLM-2 (lymphoid) ( 48 , 51 ) , HeLa (cervical) ( 30 ) , HepG2 (hepatic) ( 53 ) , Hs746T (pancreatic) ( 49 ) , HUVEC (endothelial) ( 20 ) , Jurkat (T lymphocyte) ( 22 , 24 , 33 , 36 , 37 , 55 ) , KMS-11 (B lymphocyte) ( 23 ) , KPL-4 (breast cell) ( 4 ) , LNCaP (prostate cell) ( 30 ) , lung ( 3 , 16 , 43 , 44 , 45 , 46 ) , LX-2 (hepatic stellate) ( 59 ) , MCF-10A (breast cell) ( 30 ) , MCF-7 (breast cell) ( 4 ) , MDA-IBC-3 (breast cell) ( 4 ) , MDA-MB-231 (breast cell) ( 4 ) , MDA-MB-453 (breast cell) ( 30 ) , MDA-MB-468 (breast cell) ( 4 , 30 ) , MEF (fibroblast) [SOCS3 (mouse)] ( 53 ) , MEF (fibroblast) ( 53 ) , MG63 (bone cell) ( 5 ) , MKN-45 (gastric) ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 21 , 39 , 52 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1650 (pulmonary) ( 58 ) , NCI-H1703 (squamous) ( 25 , 26 , 27 , 28 , 42 ) , NCI-H2228 (pulmonary) ( 34 , 35 ) , NCI-H3255 (pulmonary) ( 39 ) , ovary ( 41 ) , OVMANA (ovarian) ( 19 ) , PC3 (prostate cell) ( 30 ) , RD18 (muscle cell) ( 5 ) , RLMVEC (endothelial) ( 57 ) , SACC-83 (salivary gland) ( 31 ) , Saos-2 (bone cell) ( 5 ) , SKBr3 (breast cell) ( 4 ) , skin ( 29 , 32 ) , SUM149 (breast cell) ( 4 ) , SUM159 (breast cell) ( 4 ) , SUM190 (breast cell) ( 4 ) , T lymphocyte-blood ( 47 ) , T lymphocyte-lymph node ( 61 ) , thymocyte ( 61 ) , thymus ( 17 ) , U266 (plasma cell) ( 14 ) , Vero (epithelial) ( 56 )

Upstream Regulation
Regulatory protein:
SOCS3 (mouse) ( 53 ) , Tyk2 (human) ( 47 )
Kinases, in vitro:
JAK3 (human) ( 60 )
Putative upstream phosphatases:
PTPN2 (human) ( 61 )
Treatments:
AG490 ( 59 ) , cryptotanshinone ( 30 ) , gambogic_acid ( 14 ) , H2O2 ( 62 ) , IFN-alpha ( 47 , 55 ) , IFN-beta ( 47 , 56 ) , IFN-gamma ( 62 ) , IL-10 ( 3 ) , IL-2 ( 61 ) , IL-6 ( 20 ) , JAK_inhibitor_I ( 20 ) , leptin ( 59 ) , methimazole ( 62 ) , PP2 ( 57 ) , vanadate ( 57 ) , virus infection ( 56 )

References 

1

Geethadevi A, et al. (2021) Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth. Cancer Res
34380633   Curated Info

2

Chen C, et al. (2020) ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene
32029900   Curated Info

3

Hsu TI, et al. (2016) Positive feedback regulation between IL10 and EGFR promotes lung cancer formation. Oncotarget 7, 20840-54
26956044   Curated Info

4

Robertson FM, et al. (2013) Presence of anaplastic lymphoma kinase in inflammatory breast cancer. Springerplus 2, 497
24102046   Curated Info

5

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

6

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

7

Zhou J (2012) CST Curation Set: 14107; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

8

Mulhern D (2011) CST Curation Set: 12854; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Mulhern D (2011) CST Curation Set: 12855; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Moritz A (2011) CST Curation Set: 12518; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Moritz A (2011) CST Curation Set: 12371; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Moritz A (2011) CST Curation Set: 12372; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Moritz A (2011) CST Curation Set: 12374; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Prasad S, Pandey MK, Yadav VR, Aggarwal BB (2011) Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 4, 1084-94
21490133   Curated Info

15

Possemato A (2011) CST Curation Set: 11914; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Li Y (2011) CST Curation Set: 10459; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Tu Y, et al. (2011) Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 28, 15-23
20135364   Curated Info

19

Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Safhi MM, et al. (2010) Priming of signal transducer and activator of transcription proteins for cytokine-triggered polyubiquitylation and degradation by the A 2A adenosine receptor. Mol Pharmacol 77, 968-78
20185553   Curated Info

21

Moritz A (2010) CST Curation Set: 9787; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Possemato A (2009) CST Curation Set: 8804; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

St-Germain JR, et al. (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A 106, 20127-32
19901323   Curated Info

24

Possemato A (2009) CST Curation Set: 8147; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Possemato A (2009) CST Curation Set: 7155; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Possemato A (2009) CST Curation Set: 7157; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Possemato A (2009) CST Curation Set: 7156; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Possemato A (2009) CST Curation Set: 7154; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Tucker M (2009) CST Curation Set: 6393; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Shin DS, et al. (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69, 193-202
19118003   Curated Info

31

Stokes M (2008) CST Curation Set: 5670; Year: 2008; Biosample/Treatment: cell line, SACC-83/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Tucker M (2008) CST Curation Set: 5436; Year: 2008; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Possemato A (2008) CST Curation Set: 5316; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

34

Rikova K (2008) CST Curation Set: 5327; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Rikova K (2008) CST Curation Set: 5328; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Possemato A (2008) CST Curation Set: 5054; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Possemato A (2008) CST Curation Set: 5055; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Gakovic M, et al. (2008) The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. J Biol Chem 283, 18522-9
18456658   Curated Info

39

Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 692-7
18180459   Curated Info

40

Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-203
18083107   Curated Info

41

Ren H (2007) CST Curation Set: 3442; Year: 2007; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Rikova K (2007) CST Curation Set: 2869; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

43

Rikova K (2007) CST Curation Set: 2347; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Rikova K (2007) CST Curation Set: 2348; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Michaud C (2007) CST Curation Set: 2255; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Rikova K (2006) CST Curation Set: 2156; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Minegishi Y, et al. (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-55
17088085   Curated Info

48

Gu T (2006) CST Curation Set: 1935; Year: 2006; Biosample/Treatment: cell line, HDLM-2/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Guo A (2006) CST Curation Set: 1937; Year: 2006; Biosample/Treatment: cell line, Hs746T/-; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

50

Gu T (2006) CST Curation Set: 1791; Year: 2006; Biosample/Treatment: cell line, CHRF/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

51

Gu T (2006) CST Curation Set: 1624; Year: 2006; Biosample/Treatment: cell line, HDLM-2/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Guo A (2006) CST Curation Set: 1605; Year: 2006; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Stross C, et al. (2006) Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J Biol Chem 281, 8458-68
16459330   Curated Info

54

Gu T (2005) CST Curation Set: 842; Year: 2005; Biosample/Treatment: cell line, CHRF/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Zheng H, Hu P, Quinn DF, Wang YK (2005) Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol Cell Proteomics 4, 721-30
15659558   Curated Info

56

Kubota T, et al. (2005) Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol 79, 4451-9
15767445   Curated Info

57

Shajahan AN, et al. (2004) Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J Biol Chem 279, 20392-400
15007081   Curated Info

58

Rush J (2004) CST Curation Set: 7915; Year: 2004; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Cao Q, Mak KM, Ren C, Lieber CS (2004) Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways. J Biol Chem 279, 4292-304
14625304   Curated Info

60

Wang R, Griffin PR, Small EC, Thompson JE (2003) Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide. Arch Biochem Biophys 410, 7-15
12559972   Curated Info

61

Simoncic PD, et al. (2002) The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol 12, 446-53
11909529   Curated Info

62

Kim H, et al. (2001) Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol 60, 972-80
11641425   Curated Info